Tuberculosis remains the world's deadliest infectious disease, killing more than a million people annually. After decades with the same long, complicated regimens, new shorter combinations like BPaL (bedaquiline, pretomanid, linezolid) are dramatically simplifying treatment for drug-resistant TB.
What's actually going on in research
Trials are testing shorter regimens for drug-sensitive and drug-resistant TB, new drugs and drug combinations, treatments for TB in children and people living with HIV, and the M72 vaccine that may finally improve on the century-old BCG vaccine. Researchers are also studying latent TB treatment shortening.
Shorter regimens
New combinations like BPaL cut drug-resistant TB treatment from 18 to 6 months with higher cure rates. Studies are testing similar shortening for drug-sensitive TB.
New TB vaccine
The M72 vaccine showed roughly 50 percent protection against active TB in adults already infected with latent TB. Late-stage trials are now underway, with potential global impact.
TB and HIV
Many TB cases occur in people with HIV. Trials are testing how to coordinate TB and HIV treatments safely, including shorter latent TB regimens that fit alongside HIV care.
What to know before you search
Eligibility often depends on TB type (drug-sensitive or resistant), HIV status, prior treatments, and TB site (lung or other organs).
What types of trials are currently open
- Treatment trials — Testing shorter or simpler TB regimens for drug-sensitive and drug-resistant disease.
- Vaccine trials — Testing new TB vaccines like M72 to prevent active TB in adults.
- Latent TB trials — Testing shorter and easier regimens to treat latent TB infection and prevent progression.
- Pediatric trials — Testing treatments and dosing for TB in children, including drug-resistant TB.
- Observational studies — Following people with TB to understand outcomes, side effects, and resistance patterns.
Recently added Tuberculosis trials
Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis
The purpose of this study is to evaluate if TBD09 in combination with other active agents in adults with drug sensitive pulmonary tuberculosis has potential to be safe and effective.
Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis
The purpose of this study is to determine if nicotinamide in combination with bedaquiline, pretomanid, and linezolid, is safe and effective in treating drug-susceptible pulmonary tuberculosis.
Find Tuberculosis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.